SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the SCYNEXIS’s New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infections. The FDA has granted this application Priority Review, a designation which is granted to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment of serious conditions when compared to standard applications.
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 1, 2021. Additionally, the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.
The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC.
“The acceptance of this NDA marks a major milestone toward our goal of bringing to market the first new class of antifungals in over 20 years and the first new oral treatment in more than 25 years to the millions of women suffering from vaginal yeast infections,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “As the first oral, non-azole treatment for this particularly symptomatic condition, we believe ibrexafungerp has the potential to change the antifungal treatment landscape.”
Ibrexafungerp benefits from both Qualified Infectious Disease Product (QIDP) and Fast Track designations granted by the FDA for the treatment of VVC and prevention of recurrent VVC. Under QIDP designation, ibrexafungerp will receive five years of market exclusivity in addition to the five years of exclusivity as a new chemical entity.
Dr. Taglietti added, “We expect to benefit from almost 15 years of market exclusivity, which includes 10 years of regulatory exclusivity as a QIDP product and composition-of-matter patent protection until 2035. We believe this time on the market will allow us to establish ibrexafungerp as a major antifungal franchise and a key treatment option across several indications, which may help the brand attain blockbuster status.”
“In VVC alone we believe ibrexafungerp has the potential to achieve significant sales in the U.S., given the large market and the limited treatment options,” said Jim Maffezzoli, Vice President of Marketing and Sales. “With over 16 million prescriptions written each year and only one oral product to treat this condition, we believe our novel antifungal treatment has significant potential to address the needs of women and healthcare providers who are not satisfied with the standard of care. Based on ibrexafungerp’s unique collection of attributes, including its differentiated mechanism of action, we are confident that, if approved, ibrexafungerp can capture a meaningful percentage of the VVC addressable market with the potential for label expansion in the hospital setting.”
VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis. Although these infections are frequently caused by Candida albicans, fluconazole-resistant Candida
Current treatments for VVC include several topical azole antifungals (clotrimazole, miconazole, and others) and fluconazole, the only orally-administered antifungal currently approved for the treatment of VVC in the U.S. Fluconazole reported a 55% therapeutic cure rate in its label, which now also includes warnings of potential for fetal harm, illustrating the need for new oral alternatives. The needs of women with moderate-to-severe VVC, recurrent VVC, VVC caused by fluconazole-resistant Candida spp. or VVC during child-bearing age are not fully addressed by oral fluconazole or topical products. In addition, there are no oral alternatives for VVC patients who do not respond to or do not tolerate fluconazole, and there are no FDA-approved products for the prevention of recurrent VVC.
- Japan reports bird flu outbreak in Hiroshima Prefecture
- Denmark: Mink variant of SARS-CoV-2 affects more of community, Less in mink farmers
- Immunization rates dropping dramatically, Much due to the COVID-19 pandemic
- South Carolina reports 16th EEE case in a horse, 3rd in Aiken County
- Dengue fever in the Americas: Lowest case fatality rate in 10 years
- Philippines COVID-19: 1,768 new confirmed cases, Police to enforce social distancing with rattan sticks in Manila
- NYU Langone study: Once hospitalized, black patients with COVID-19 have lower risk of death than white